Indication
Stage IV Childhood Lymphoblastic Lymphoma
1 clinical trial
13 products
2 drugs
Clinical trial
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)Status: Active (not recruiting), Estimated PCD: 2020-03-31
Product
BortezomibDrug
cyclophosphamideProduct
CytarabineProduct
DaunorubicinProduct
DexamethasoneProduct
DoxorubicinProduct
EtoposideProduct
HydrocortisoneProduct
IfosfamideProduct
LeucovorinProduct
MercaptopurineProduct
MethotrexateProduct
PegaspargaseProduct
ThioguanineDrug
Vincristine